Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2011 / Cilt: 20 - Sayı: 1

Kronik böbrek yetmezliği hastalarında koroner arter hastalığı ciddiyeti ile “asymmetrical dimethylarginine” arasındaki ilişki

Association between asymmetric dimethylarginine and the severity of coronary artery disease in patients with chronic kidney disease

Pages
58–64
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In a multivariate regression model, ADMA was the only statistically significant independent predictor of Gensini score.CONCLUSION: ADMA appears to be one of the strongest risk markers for atherosclerosis in patients with mild and moderate CKD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Cardiovascular diseases are the most common cause of death in patients with endstage renal disease.
📊
Key Findings & Data:Asymmetrical dimethylarginine (ADMA) is increased in conditions associated with increased risk of atherosclerosis.
💡
Conclusion & Impact:In a multivariate regression model, ADMA was the only statistically significant independent predictor of Gensini score.CONCLUSION: ADMA appears to be one of the strongest risk markers for atherosclerosis in patients with mild and moderate CKD.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Cardiovascular diseases are the most common cause of death in patients with endstage renal disease. Asymmetrical dimethylarginine (ADMA) is increased in conditions associated with increased risk of atherosclerosis. We aimed to examine the association between severity of coronary stenosis and the ADMA levels in a group of chronic kidney disease (CKD) stage 1 to 3.MATERIAL and METHODS: Eighty-eight (88) consecutive patients with decreased renal function (glomerular filtration rate (GFR) between 90 and 30 ml/min), undergoing cardiac catheterization for proven or clinically suspected coronary artery disease were enrolled at the study. Serum levels of creatinine, ADMA, nitric oxide (NO), calcium, phosphate, total cholesterol, HDL and LDL fractions, triglycerides were determined using measurement techniques. The Gensini scoring system was used for the detection of the severity of coronary atherosclerosis.RESULTS: The mean serum values were 81.48 ± 13.8 micromol/l for ADMA and 3.7 ± 1.7 mmol/L for NO. The mean Gensini score in the study group was 30.4 ± 40.1. All patients were classified into tertiles of Gensini score level. Patients in the highest tertile had statistically significantly lower GFR values. The ADMA values increased statistically significantly in the third tertile compared with the first tertile. The Gensini score values significantly correlated in univariate analysis with the GFR, ADMA and presence of hypertension. In a multivariate regression model, ADMA was the only statistically significant independent predictor of Gensini score.CONCLUSION: ADMA appears to be one of the strongest risk markers for atherosclerosis in patients with mild and moderate CKD.

Özet

AMAÇ: Son dönem böbrek yetmezliği hastalarında en genel ölüm sebebi kardiyovasküler hastalıklardır. Asymmetrical dimethylarginine (ADMA) aterosklerozis riskinin artması ile ilişkili durumlarda artmaktadır. Bu çalışmada amaç, kronik böbrek yetmezliği evre 1-3 grubunda, koroner arter darlığı ciddiyeti ile ADMA düzeyleri arasındaki ilişkiyi saptamaktır.GEREÇ ve YÖNTEMLER: Böbrek işlevleri azalmış, klinik koroner arter hastalığı kuşkusu veya kanıtlanmış koroner arter hastalığı ile koroner anjiyografi yapılan 88 hasta çalışmaya alındı. Serum kreatinin, ADMA, nitrik oksit (NO), kalsiyum, fosfat, total kolesterol, HDL, LDL fraksiyonları ve trigliserid düzeyleri ölçüldü. Koroner aterosklerozis ciddiyetini belirlemek için Gensini skorlama sistemi kullanıldı.BULGULAR: Ortalama serum düzeyleri ADMA için 81.48±13.8 micromol/l, NO için 3.7±1.7 milimol/L ölçüldü. Bu çalışmada ortalama Gensini skoru olarak 30.4±40.1. saptandı. Tüm hastalar Gensini skoruna göre üç gruba ayrıldı. En yüksek gruptaki hastaların glomerüler filtrasyon hızı (GFR) düzeyleri istatiksel olarak anlamlı derecede düşük saptandı. İlk grupla karşılaştırıldığında üçüncü grupta ADMA düzeyleri anlamlı olarak yüksekti. Tek değişkenli analizde Gensini skoru değerlerinin, ADMA düzeyleri, GFR ve hipertansiyon mevcudiyeti ile uyumlu olduğu saptandı. Çok değişkenli regresyon modelinde, yalnızca ADMA düzeyi Gensini skoru için bağımsız bir belirleyici etken olduğu saptandı.SONUÇ: Hafif-orta dereceli kronik böbrek yetmezliği hastalarında, ADMA düzeyleri ateroskleroz için güçlü bir belirteç olarak görülmektedir.

🔖

Cite This Article

ARMUTÇU, F., SELCOKİ, Y., KANBAY, M., İKİZEK, M., ERYONUCU, B., AYDIN, M. (2022). Kronik böbrek yetmezliği hastalarında koroner arter hastalığı ciddiyeti ile “asymmetrical dimethylarginine” arasındaki ilişki. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 20 - Sayı: 1, 58–64. https://ajindex.com/articles/636455

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Stenvinkel P, Alvestrand P: Inflammation in end-stage renal disease: Sources, consequences and therapy. Seminar Dial 2002; 15: 330-338 2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant of uremia: Oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538 3. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S: Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007; 11: 115-121 4. Zoccali C, Kielstein JT: Asymmetric dimethylarginine: A new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens 2006; 15: 314-320 5. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575 6. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847 7. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-116 8. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426 9. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203 10. Stuhlinger MC, Stanger O: Asymmetric dimethyl-L-arginine (ADMA): A possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005; 6: 3-14 11. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658 12. Zoccali C: Asymmetric dimethylarginine (ADMA): A cardiovascular and renal risk factor on the move. Journal of Hypertension 2006; 24: 611-619 1